Fadi S Dahdaleh1, Samer A Naffouje2,3, Mark H Hanna4, George I Salti5,2. 1. Department of Surgical Oncology, Edward-Elmhurst Health, 120 Spalding Drive, Ste 205, Naperville, IL, 60540, USA. Fadi.Dahdaleh@EEHealth.org. 2. Department of General Surgery, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA. 3. Department of Surgical Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA. 4. Department of Colon and Rectal Surgery, Surgical Oncology, City of Hope Medical Foundation, Upland, CA, USA. 5. Department of Surgical Oncology, Edward-Elmhurst Health, 120 Spalding Drive, Ste 205, Naperville, IL, 60540, USA.
Abstract
INTRODUCTION: Postoperative pancreatic fistula (POPF) drives morbidity and mortality following pancreatectomy. Use of neoadjuvant chemotherapy (NAC) has recently increased in the treatment of potentially resectable pancreatic ductal adenocarcinoma (PDAC). This study examined the effect of NAC on POPF rates and postoperative outcomes in PDAC. METHODS: The American College of Surgeons-National Surgical Quality Improvement Program (NSQIP) Targeted Pancreatectomy dataset was queried to identify PDAC patients who underwent curative-intent pancreatectomies. Propensity score matching was used to stratify patients by receipt of NAC. Postoperative outcomes were compared and logistic regression applied to identify POPF predictors. RESULTS: Six thousand eight hundred sixty-three patients met the inclusion criteria; of those, 1908 (27.8%) received NAC and 4955 (72.2%) did not (NNAC). Two thousand sixty-two patients were matched 1:1 from each group. NAC patients had significantly lower POPF rates (9.0% vs. 14.5%; P < 0.001); the majority were categorized as grade A (5.1% vs. 9.5%). Overall 30-day morbidity was lower with NAC (40.4% vs. 49.5%; P < 0.001). Specifically, pneumonia (2.3% vs. 4.1%), organ space infections (7.9% vs. 13.2%), sepsis (5.2% vs. 8.0%), and delayed gastric emptying (10.1% vs. 14.8%) occurred less frequently in the NAC group. Postoperative mortality and unplanned reoperations were similar. On multivariate analysis, receipt of NAC was an independent predictor of decreased POPF rates (HR, 0.73 [0.56-0.94]; P = 0.016). Other factors included gland texture, duct size, male gender, and lower BMI. CONCLUSIONS: In this propensity-matched, population-based cohort study of PDAC patients, NAC was associated with lower POPF rates and overall major complications. Those findings suggest a modest protective effect of NAC from POPF.
INTRODUCTION:Postoperative pancreatic fistula (POPF) drives morbidity and mortality following pancreatectomy. Use of neoadjuvant chemotherapy (NAC) has recently increased in the treatment of potentially resectable pancreatic ductal adenocarcinoma (PDAC). This study examined the effect of NAC on POPF rates and postoperative outcomes in PDAC. METHODS: The American College of Surgeons-National Surgical Quality Improvement Program (NSQIP) Targeted Pancreatectomy dataset was queried to identify PDACpatients who underwent curative-intent pancreatectomies. Propensity score matching was used to stratify patients by receipt of NAC. Postoperative outcomes were compared and logistic regression applied to identify POPF predictors. RESULTS: Six thousand eight hundred sixty-three patients met the inclusion criteria; of those, 1908 (27.8%) received NAC and 4955 (72.2%) did not (NNAC). Two thousand sixty-two patients were matched 1:1 from each group. NACpatients had significantly lower POPF rates (9.0% vs. 14.5%; P < 0.001); the majority were categorized as grade A (5.1% vs. 9.5%). Overall 30-day morbidity was lower with NAC (40.4% vs. 49.5%; P < 0.001). Specifically, pneumonia (2.3% vs. 4.1%), organ space infections (7.9% vs. 13.2%), sepsis (5.2% vs. 8.0%), and delayed gastric emptying (10.1% vs. 14.8%) occurred less frequently in the NAC group. Postoperative mortality and unplanned reoperations were similar. On multivariate analysis, receipt of NAC was an independent predictor of decreased POPF rates (HR, 0.73 [0.56-0.94]; P = 0.016). Other factors included gland texture, duct size, male gender, and lower BMI. CONCLUSIONS: In this propensity-matched, population-based cohort study of PDACpatients, NAC was associated with lower POPF rates and overall major complications. Those findings suggest a modest protective effect of NAC from POPF.
Authors: Thilo Hackert; Milena Sachsenmaier; Ulf Hinz; Lutz Schneider; Christoph W Michalski; Christoph Springfeld; Oliver Strobel; Dirk Jäger; Alexis Ulrich; Markus W Büchler Journal: Ann Surg Date: 2016-09 Impact factor: 12.969
Authors: Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet Journal: N Engl J Med Date: 2018-12-20 Impact factor: 91.245
Authors: Peter J Allen; Deborah Kuk; Carlos Fernandez-Del Castillo; Olca Basturk; Christopher L Wolfgang; John L Cameron; Keith D Lillemoe; Cristina R Ferrone; Vicente Morales-Oyarvide; Jin He; Matthew J Weiss; Ralph H Hruban; Mithat Gönen; David S Klimstra; Mari Mino-Kenudson Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Theodoros Michelakos; Ilaria Pergolini; Carlos Fernández-Del Castillo; Kim C Honselmann; Lei Cai; Vikram Deshpande; Jennifer Y Wo; David P Ryan; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Janet E Murphy; Ryan D Nipp; Aparna Parikh; Motaz Qadan; Andrew L Warshaw; Theodore S Hong; Keith D Lillemoe; Cristina R Ferrone Journal: Ann Surg Date: 2019-04 Impact factor: 12.969
Authors: John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler Journal: JAMA Date: 2010-09-08 Impact factor: 56.272
Authors: Eva Versteijne; Casper H J van Eijck; Cornelis J A Punt; Mustafa Suker; Aeilko H Zwinderman; Miriam A C Dohmen; Karin B C Groothuis; Oliver R C Busch; Marc G H Besselink; Ignace H J T de Hingh; Albert J Ten Tije; Gijs A Patijn; Bert A Bonsing; Judith de Vos-Geelen; Joost M Klaase; Sebastiaan Festen; Djamila Boerma; Joris I Erdmann; I Quintus Molenaar; Erwin van der Harst; Marion B van der Kolk; Coen R N Rasch; Geertjan van Tienhoven Journal: Trials Date: 2016-03-09 Impact factor: 2.279
Authors: Robert W Krell; Logan R McNeil; Ujwal R Yanala; Chandrakanth Are; Bradley N Reames Journal: Ann Surg Oncol Date: 2021-01-01 Impact factor: 5.344
Authors: Christopher Ryan Deig; Thomas Lee Sutton; Blake Beneville; Kristin Trone; Amanda Stratton; Ali N Gunesch; Amy Ivy Liu; Alaaeddin Alrohaibani; Maedeh Mohebnasab; Solange Bassale; Alison Grossblatt-Wait; Dove Keith; Fouad Attia; Erin W Gilbert; Charles D Lopez; Adel Kardosh; Emerson Y Chen; Kenneth G Bensch; Nima Nabavizadeh; Charles R Thomas; Skye C Mayo; Brett C Sheppard; Aaron Grossberg Journal: Cancers (Basel) Date: 2022-01-26 Impact factor: 6.639